 | • レポートコード：MRC2203A777 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料では、世界の抗凝固剤市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤分類別（新規経口抗凝固薬（NOAC）、ヘパリン＆低分子量ヘパリン（LMWH）、ビタミンK拮抗薬）分析、用途別（心房細動/心筋梗塞（心臓発作）、深部静脈血栓症（DVT）、肺塞栓症、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の抗凝固剤市場規模：薬剤分類別（新規経口抗凝固薬（NOAC）、ヘパリン＆低分子量ヘパリン（LMWH）、ビタミンK拮抗薬） ・世界の抗凝固剤市場規模：用途別（心房細動/心筋梗塞（心臓発作）、深部静脈血栓症（DVT）、肺塞栓症、その他） ・世界の抗凝固剤市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Johnson & Johnson、Bayer AG、Boehringer Ingelheim GmbH、...） ・市場機会・将来の傾向 |
The Anticoagulants Market is expected to register a CAGR of 9.41% during the forecast period. Anticoagulants are used to treat and prevent blood clots which can block blood vessels (an artery or a vein) that can lead to serious complications as the clot disrupts the flow of blood to important organs and can result in heart attack and stroke.
A blood clot is a seal created by the blood to stop bleeding from wounds. Most prescribed anticoagulant is warfarin. Some of the newer types of anticoagulants are edoxaban, apixaban, dabigatran, and rivaroxaban.
According to the World Health Organization (WHO), globally cardiovascular diseases (CVDs) are the number 1 cause of death, an estimated 17.9 million each year suffer from cardiovascular diseases. Four out of 5 cardiovascular deaths are due to strokes and heart attacks, and one-third of deaths occur prematurely in people under 70 years of age.
Furthermore, increasing cases of chronic diseases, unhealthy lifestyles adopted by individuals, and growing adoption of novel oral anticoagulants (NOACs) are the key driving factors in anticoagulants market.
Key Market Trends
Novel Oral Anticoagulants (NOACs) Segment is Expected to Hold Significant Market Share in the Anticoagulants Market
Novel Oral Anticoagulants (NOACs) segment holds a significant market share in the anticoagulants market and is anticipated to show a similar trend over the forecast period owing to the growing adoption of the novel oral anticoagulants (NOACs) in developing countries and high preference of NOACs over the warfarin. Novel oral anticoagulants (NOACs) are a new class of anticoagulant drugs. Moreover, these are safe (lower incidence of major bleeding), convenient to use, no interactions with food, and shorter half-life. Some of the NOACs include dabigatran, rivaroxaban, apixaban, and edoxaban. These can be used in the prevention and treatment of atrial fibrillation/myocardial infarction, deep vein thrombosis (DVT) and pulmonary embolism.
According to the Centers for Disease Control and Prevention (CDC), each year in the United States approximately 900,000 people ((1 to 2 per 1,000 population) could be affected with deep vein thrombosis. Moreover, about 60,000-100,000 Americans die of deep vein thrombosis. The increasing incidences of cardiovascular disorders, venous thromboembolism (VTE), and technological advancements in the development of novel products are the key driving factors in the novel oral anticoagulants (NOACs) segment.
North America Holds the Largest Share by Revenue in the Market
North America is expected to hold a major market share in the global anticoagulants market due to the high demand for innovative products, and the increasing prevalence of cardiovascular disorders in this region. According to the American Heart Association Research, approximately 2,300 Americans die due to cardiovascular diseases each day, an average of one death every 38 seconds. Furthermore, the presence of top pharma and biotech companies that are involved in the development of therapeutics and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
Competitive Landscape
The Anticoagulants Market is fragmented competitive and consists of several major players. Some of the major players operating in the market include Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, GlaxoSmithKline Plc, Aspen Holdings, Sanofi, Pfizer, Inc and Portola Pharmaceuticals, Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Cases of Chronic Diseases
4.2.2 Technological Advancements in Development of Anticoagulant Products
4.2.3 Growing Adoption of Novel Oral Anticoagulants (NOACs)
4.3 Market Restraints
4.3.1 Stringent Government Regulations
4.3.2 Side Effects Associated with Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Novel Oral Anticoagulants (NOACs)
5.1.2 Heparin and Low Molecular Weight Heparin (LMWH)
5.1.3 Vitamin K Antagonist
5.2 By Application
5.2.1 Atrial Fibrillation/Myocardial Infarction (Heart Attack)
5.2.2 Deep Vein Thrombosis (DVT)
5.2.3 Pulmonary Embolism
5.2.4 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Johnson & Johnson
6.1.2 Bayer AG
6.1.3 Boehringer Ingelheim GmbH
6.1.4 Bristol-Myers Squibb Company
6.1.5 Daiichi Sankyo Company
6.1.6 Abbott Laboratories
6.1.7 Aspen Holdings
6.1.8 Sanofi
6.1.9 Pfizer, Inc
6.1.10 Alexion Pharmaceuticals Inc.
6.1.11 Leo Pharma AS
6.1.12 Dr. Reddy’s Laboratories
7 MARKET OPPORTUNITIES AND FUTURE TRENDS